In Jun 2024, the professional team from VCRO assisted the client in submitting the clinical trial application of their small molecule pharmaceuticals for the treatment of EGFR-mutant non-small cell lung cancer. The team successfully obtained FDA approval to proceed with Phase I clinical trials. We successfully supported our clients in smoothly advancing to the Phase I clinical trial stage. VCRO is here to accompany you through every stage of the clinical trial process.
